Clinical Trial Update: [68 Ga]-DOTANOC PET/CT in GEP-NETs [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 trial evaluating [68 Ga]-DOTANOC PET/CT imaging in gastroenteropancreatic neuroendocrine tumors has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroenteropancreatic Neuroendocrine Tumors

Drugs mentioned

• [68 Ga]-DOTANOC (DOTANOC labeled with Gallium-68)

Snippet

Sponsor: Assistance Publique Hopitaux De Marseille | Conditions: Gastroenteropancreatic Neuroendocrine Tumors | Phase 2, Phase 3 | Status: COMPLETED